Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid open-label extension study in high cardiovascular risk patients with hyperlipidemia
2016-004115-12Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bempedoic acid in hypercholesterolemia and hyperlipidemia, sponsored by Esperion Therapeutics. Primary endpoint: Incidence of adverse events. Started Mar 2017; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemiahyperlipidemia
Beyond the preview
Go deeper on 2016-004115-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004115-12.